TCTMD’s Top 10 Most Popular Stories for December 2017
The list this month is one of the widest-ranging collections of the year, touching on coronary disease, valves, multiple sclerosis, and DVT.
In what might be the widest-ranging list of this year’s top news, the most-read stories for the month of December 2017 ranged from new stents to diabetes remission, a no-go for a drug-device combo in deep vein thrombosis, and the failure of “liberation therapy” in multiple sclerosis.
The guidance, covering all drug indications, complements a prior document on periprocedural management of anticoagulation.
The device, which has the narrowest strut width of any stent on the market, was approved on the basis of the nearly 2,000-patient BIONICS study.
The pioneer for the controversial technique who led the Brave Dreams trial now says “liberation therapy” is ineffective and warrants no further study.
Performing one physiologic assessment or the other seems to be more important than whether FFR or iFR is chosen, Allen Jeremias says.
The dose-response effect seen with strict dietary intervention—allowing just 850 kcal/day—supports the link between diabetes and body fat.
The study reaffirms what was observed in the large EXCEL trial, suggesting PCI is an acceptable option in left main disease, say researchers.
Procedural outcomes are better with more recent valve models, with moderate or worse postprocedural AR linked to higher mortality.
Multivessel PCI is linked to less death and MI when done all at once, but not when done in a staged fashion.
Reactions to ORBITA ranged from a lone call to downgrade PCI in stable patients to declarations that the provocative trial will have zero impact.
The ATTRACT trial failed to meet its primary endpoint, but there may remain a role for the approach in some patients.